Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Faron Pharmaceuticals Oy    FARN   FI4000153309

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/23/2017 Date
830(c) 830(c) 832.5(c) 837.5(c) 831.25 Last
2 726 500 20 778 3 720 196 Volume
-0.30% 0.00% +0.30% +0.60% -0.75% Change
More quotes
Financials ( GBP)
Sales 2017 0,36 M
EBIT 2017 -14,1 M
Net income 2017 -12,9 M
Finance 2017 11,3 M
Yield 2017 -
Sales 2018 3,05 M
EBIT 2018 -13,6 M
Net income 2018 -13,8 M
Debt 2018 2,68 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 653x
EV / Sales2018 81,0x
Capitalization 244 M
More Financials
Company
Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development.The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage.It operates through the Traumakine and Clevegen brands for acute respiratory... 
More about the company
Latest news on FARON PHARMACEUTICALS OY
10/12 FARON PHARMACEUTICALS OY : Results of the Placing and Subscription and Issue of ..
09/14 FARON PHARMACEUTICALS OY : Director's Dealing
09/11 FARON PHARMACEUTICALS OY : Ltd - Interim Results for the six months ended 30 Jun..
09/07 FARON PHARMACEUTICALS OY : FDA advises Faron to proceed directly to BLA
09/06 FARON PHARMACEUTICALS OY : Interim Results for the six months ended 30 June 2017
09/04 FARON PHARMACEUTICALS OY : Faron announces that US FDA proposes proceeding direc..
09/01FARON PHARMACEUTICALS OY : half-yearly earnings release
08/04 FARON PHARMACEUTICALS OY : Update on INTEREST Phase III Study from IDMC
07/10 FARON PHARMACEUTICALS OY : Notice of Results
06/01 FARON PHARMACEUTICALS OY : Exercise of Warrants and Options Issue of Equity
More news
Sector news : Bio Therapeutic Drugs
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | 4-Traders
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,17  GBP
Spread / Average Target -14%
Managers
NameTitle
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Frank Murdoch Armstrong Non-Executive Chairman
Mikael Maksimow Vice President-Operations
Yrjö Erik Kristian Wichmann Chief Financial Officer & Executive Director
Matti Karvonen Chief Medical Officer & VP-Drug Development
Sector and Competitors
1st jan.Capitalization (M$)
FARON PHARMACEUTICALS OY216.04%326
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS4.73%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731